Abstract
Assessing health technology in cancer screening requires stringent evidence-based criteria with which efficacy can be judged, coupled with sensible health-economic analyses of any new intervention strategy. For efficacy, the highest level of evidence comes from showing—in a randomised controlled trial—that implementation of a new screening technology reduces cancer-specific mortality compared with the existing standard of practice. Although this point has been reached recently for human papillomavirus (HPV) DNA testing in cervical cancer in a landmark study conducted in India,1 it is unlikely that this high-level evidence will be used on its own to inform policy decisions on cancer control in developed countries.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call